PMID- 20957629
OWN - NLM
STAT- MEDLINE
DCOM- 20110930
LR  - 20160303
IS  - 1097-0215 (Electronic)
IS  - 0020-7136 (Linking)
VI  - 129
IP  - 4
DP  - 2011 Aug 15
TI  - Bacillus Calmette-Guerin immunotherapy of bladder cancer induces selection of 
      human leukocyte antigen class I-deficient tumor cells.
PG  - 839-46
LID - 10.1002/ijc.25733 [doi]
AB  - Bacillus Calmette-Guerin (BCG) immunotherapy is a standard treatment for 
      high-risk non-muscle-infiltrating bladder cancer patients. Although the outcomes 
      are good, cancer relapse is observed in around 40% of patients. We present the 
      comparative analysis of human leukocyte antigen (HLA) class I expression in 
      recurrent bladder tumors in patients treated with mitomycin or BCG. HLA class I 
      expression was analyzed by RT-Q-PCR and immunohistochemical techniques. Loss of 
      heterozygosity (LOH) was determined by microsatellite amplification of markers in 
      chromosome 6 and 15. More profound alterations in HLA class I expression were 
      found in post-BCG recurrent tumors than in pre-BCG lesions, whereas mitomycin 
      treatment did not change the HLA class I expression pattern. Post-BCG recurrent 
      tumors also showed a higher incidence of structural defects underlying altered 
      HLA class I expression. We hypothesize that the immunotherapy-activated immune 
      system recognizes and eliminates tumor cells with reversible ("soft") HLA class I 
      changes but not transformed cells with additional, irreversible ("hard") 
      alterations. To our knowledge, this is the first clinical evidence of 
      immunotherapy-induced immunoselection of HLA class I loss tumor variants in 
      bladder cancer, although the study involved a small number of patients.
CI  - Copyright (c) 2010 UICC.
FAU - Carretero, Rafael
AU  - Carretero R
AD  - Department of Clinical Analysis, Virgen de las Nieves University Hospital, and 
      Department of Biochemistry, Molecular Biology III and Immunology, University of 
      Granada, Spain.
FAU - Cabrera, Teresa
AU  - Cabrera T
FAU - Gil, Hernani
AU  - Gil H
FAU - Saenz-Lopez, Pablo
AU  - Saenz-Lopez P
FAU - Maleno, Isabel
AU  - Maleno I
FAU - Aptsiauri, Natalia
AU  - Aptsiauri N
FAU - Cozar, Jose M
AU  - Cozar JM
FAU - Garrido, Federico
AU  - Garrido F
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110610
PL  - United States
TA  - Int J Cancer
JT  - International journal of cancer
JID - 0042124
RN  - 0 (Adjuvants, Immunologic)
RN  - 0 (Antibiotics, Antineoplastic)
RN  - 0 (BCG Vaccine)
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (RNA, Messenger)
RN  - 50SG953SK6 (Mitomycin)
SB  - IM
MH  - Adjuvants, Immunologic/*administration & dosage
MH  - Adult
MH  - Aged
MH  - Antibiotics, Antineoplastic/therapeutic use
MH  - BCG Vaccine/*administration & dosage/immunology
MH  - Histocompatibility Antigens Class I/genetics/*metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - *Immunotherapy
MH  - Loss of Heterozygosity
MH  - Male
MH  - Middle Aged
MH  - Mitomycin/therapeutic use
MH  - Neoplasm Recurrence, Local/*diagnosis/immunology/metabolism
MH  - Predictive Value of Tests
MH  - RNA, Messenger/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Treatment Outcome
MH  - Urinary Bladder Neoplasms/*immunology/*therapy
EDAT- 2010/10/20 06:00
MHDA- 2011/10/01 06:00
CRDT- 2010/10/20 06:00
PHST- 2010/06/11 00:00 [received]
PHST- 2010/09/27 00:00 [accepted]
PHST- 2010/10/20 06:00 [entrez]
PHST- 2010/10/20 06:00 [pubmed]
PHST- 2011/10/01 06:00 [medline]
AID - 10.1002/ijc.25733 [doi]
PST - ppublish
SO  - Int J Cancer. 2011 Aug 15;129(4):839-46. doi: 10.1002/ijc.25733. Epub 2011 Jun 
      10.